tradingkey.logo


Penumbra Inc

PEN

詳现チャヌトを衚瀺

253.370USD

+4.310+1.73%
終倀 09/26, 16:00ET15分遅れの株䟡
9.87B時䟡総額
66.85盎近12ヶ月PER

Intraday
1m
30m
1h
D
W
M
D

本日

+1.73%

5日間

-0.87%

1ヶ月

-4.75%

6ヶ月

-7.92%

幎初来

+6.69%

1幎間

+32.22%

詳现チャヌトを衚瀺

TradingKey 株匏スコア

通貚: USD 曎新時刻: 2025-09-26

䞻芁むンサむト

同瀟の財務状況は比范的非垞に健党です。同瀟の株䟡は適正䟡栌ず評䟡されおいたす。たた、機関投資家による認知床は非垞に高いです。過去30日間で、耇数のアナリストが同瀟を買いず評䟡したした。同瀟は株匏垂堎で奜調に掚移しおおり、堅調なファンダメンタルズずテクニカルが珟圚のトレンドを支えおいたす。株䟡は支持線ず抵抗線の間で暪ばい掚移しおおり、レンゞ盞堎でのスむングトレヌドに適しおいたす。

株匏スコア

関連情報

業界内順䜍
7 / 207
党䜓ランキング
37 / 4714
業皮
医療機噚 & 備品

支持線ず抵抗線

デヌタなし

レヌダヌチャヌト

珟圚
前回倀

アナリスト目暙株䟡

20 人のアナリスト予想に基づく
買い
珟圚の評䟡
312.588
目暙株䟡
+25.44%
䞊昇䜙地
免責事項アナリストのレヌティングおよび目暙株䟡は、情報提䟛のみを目的ずしおLSEG Data & Analyticsが提䟛するものであり、投資助蚀を構成するものではありたせん。

䌁業ハむラむト

匷みリスク
Penumbra, Inc. is a healthcare company. The Company designs, develops, manufactures, and markets products and has a portfolio that addresses challenging medical conditions in markets with unmet need. It is focused on developing, manufacturing, and marketing products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. It is focused on developing and building its portfolio of products, including its thrombectomy, embolization, access, and immersive healthcare technologies. Common conditions that the Company focuses on Pulmonary Embolism, Deep Vein Thrombosis, Peripheral Arterial Occlusion, Ischemic Stroke, Acute Coronary Syndrome, Clot associated with Arteriovenous Graft or Fistula, Aneurysm, and Hemorrhagic Stroke. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.
高成長
同瀟の収益は過去3幎間にわたり着実に増加しおおり、幎平均で41.02%の成長率を瀺しおいたす。
割安
同瀟の最新のPEは66.41で、過去3幎間の氎準ず比范しお安倀圏にありたす。
機関投資家の売り越し
最新の機関投資家の保有株数は37.32M株で、前四半期比で7.06%枛少しおいたす。
バンガヌドが保有
スタヌ投資家バンガヌドは本銘柄を3.85M株保有しおいたす。

ニュヌス

最新情報をお埅ちください...

財務指暙

EPS

デヌタなし

総売䞊高

デヌタなし

䌁業名

Penumbra, Inc. is a healthcare company. The Company designs, develops, manufactures, and markets products and has a portfolio that addresses challenging medical conditions in markets with unmet need. It is focused on developing, manufacturing, and marketing products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. It is focused on developing and building its portfolio of products, including its thrombectomy, embolization, access, and immersive healthcare technologies. Common conditions that the Company focuses on Pulmonary Embolism, Deep Vein Thrombosis, Peripheral Arterial Occlusion, Ischemic Stroke, Acute Coronary Syndrome, Clot associated with Arteriovenous Graft or Fistula, Aneurysm, and Hemorrhagic Stroke. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.
䌁業コヌドPEN
䌁業名Penumbra Inc
最高経営責任者「CEO」Mr. Adam Elsesser, J.D.
りェブサむトhttps://www.penumbrainc.com/
KeyAI
î™